Mediterranean diet may reduce risk of breast cancer returning, study suggests

Mediterranean diet may reduce risk of breast cancer returning, study suggests

A new drug therapy shows promise for treating triple-negative breast cancer, an especially aggressive form of the disease, researchers say.

Clinical trial results show the combination of abdominal and IV chemotherapy can slow the progression of ovarian cancer better than IV chemo by itself in women who already have had surgery to remove all or almost all of their cancer.

Previously, in a study of 209 ER+ patients with 1-3 positive lymph nodes from the landmark TransATAC trial, the BCI algorithm was optimized by incorporating tumor size and grade to develop a new BCI prognostic model specifically for patients with lymph node-positive breast cancer. Such tests now cost around £2,000 - around half the cost of a £4,000 course of chemotherapy.

"Further studies with more women are needed to understand more about the impact that diet can have on breast cancer survival and the biological reasons behind this". OBI is also developing next generation active immunotherapies for hard to treat cancers, including lung, prostate, pancreatic, stomach, and ovarian.

As concerns recurrence of the initial cancer - most frequently in the bones, liver or other organs - the difference between the two groups was smaller - 5.7 percent in the letrozole group versus 7.1 percent in the control group.

Surgery to remove the primary tumor in women diagnosed with stage IV breast cancer, followed by the standard combination of therapies, adds months to the patients' lives, compared with standard therapy alone, an global clinical trial led by a University of Pittsburgh Cancer Institute (UPCI) professor revealed.

"This approach introduces a new era of follow-up in which patients can give and receive continuous feedback between visits", said lead author Dr. Fabrice Denis, a cancer researcher in Le Mans, France.

Sumanta Kumar Pal of City of Hope National Medical Center, who did not take part in the research, said the study also "underscores the need to explore this genomic-based testing and treatment approach in a learning environment, like a clinical trial". Majority had estrogen receptor-positive breast cancer, Goss' team said. The findings also are important in light of results of the phase III GOG 252 study, presented at the 2016 Annual Meeting of the Society of Gynecologic Oncology in March, which suggested that IP therapy was not superior to IV treatment.

Anti-hormone drugs work by either reducing oestrogen in the body (known as aromatase inhibitors), by blocking the receptors themselves (tamoxifen), or by destroying the receptors entirely (fulvestrant). Globo H is expressed in high levels on the surface of Malignant tumors in many epithelial cancers, such as breast, prostate, gastric, lung, colon, pancreatic, and ovarian cancer, etc. "But for other blood cancer types, such as CLL, we have made progress, but still have some way to go", he added. The validated instrument has also been used to identify advanced cancer patients who may be appropriate for palliative care/hospice consultations, potentially re-aligning treatment goals and reducing unwanted, expensive, technology-driven end-of-life care.